Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kimberly Davidson

Procedural Dermatology Naples, FL Medical Doctor

NPI 1770559510 CMS profile 261775

1015 Crosspointe Dr, Naples, FL 34110

Open in the dashboard

General payments

$4,535

183 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Davidson of Naples, FL is reported in the CMS Open Payments database as having received $4,535 across 183 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $668 23
2024 General $926 30
2023 General $692 33
2022 General $651 22
2021 General $525 24
2020 General $315 17
2019 General $759 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Davidson
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Kimberly Davidson were reported at $668. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Kimberly Davidson Procedural Dermatology median Middle half National median
2019 $759 $454 $152–$1,260 $163
2020 $315 $243 $90–$835 $114
2021 $525 $337 $102–$1,128 $132
2022 $651 $443 $119–$1,654 $149
2023 $692 $583 $137–$1,838 $160
2024 $926 $611 $132–$1,835 $164
2025 $668 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $701 36 payments
  2. Merz North America, Inc. $635 12 payments
  3. Revance Therapeutics, Inc. $630 12 payments
  4. Galderma Laboratories, L.P. $280 17 payments
  5. AbbVie, Inc. $247 11 payments
  6. VYNE Pharmaceuticals Inc. $225 8 payments
  7. Pfizer Inc. $196 12 payments
  8. Mayne Pharma Inc. $185 8 payments
  9. Genzyme Corporation $180 7 payments
  10. LEO Pharma Inc. $173 7 payments
  11. Other $1,083 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,535 183 payments
Products named General payments · program years 2019–2025
  1. DAXXIFY $630 12 payments
  2. Winlevi $419 19 payments
  3. Absorica LD $339 16 payments
  4. DUPIXENT $251 9 payments
  5. BLU-U $219 14 payments
  6. AMZEEQ $217 7 payments
  7. Xeomin $190 5 payments
  8. ENSTILAR $173 7 payments
  9. EUCRISA $172 11 payments
  10. VTAMA $169 7 payments
  11. Other $2,005 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,324

Median for Dermatology: 534

Drug cost

$20,986

Median for Dermatology: $67,151

Branded share of claims

10.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metronidazole Generic 67 $3,845
Fluocinonide Generic 99 $2,920
Ketoconazole Generic 191 $2,903
Triamcinolone Acetonide Generic 254 $2,137
Clobetasol Propionate Generic 49 $1,673
Valacyclovir Valacyclovir Hcl Brand 119 $1,365
Fluorouracil Generic 23 $1,237
Doxycycline Hyclate Generic 74 $996
Cephalexin Generic 150 $643
Clindamycin Phosphate Generic 22 $583

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$570,985

Of which drugs: $24,164

Medicare patients

1,896

Average age 77

Services billed

9,746

1,112 women, 784 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 52%
Ischemic heart disease 36%
Osteoporosis 21%
Diabetes 20%
Chronic kidney disease 20%
Cancer 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 54 79 $24,157

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $427
$427 — —
VTAMA
  • Dermavant Sciences, Inc. $78
$78 — —
OPZELURA
  • Incyte Corporation $75
$75 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $41
$41 — —
DYSPORT
  • Galderma Laboratories, L.P. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record